Keywords: Joint, biomarkers, DCEMRI; Rheumatoid Arthritis; Treatment Response
Motivation: Eliminate physiologically unrealistic results that sometimes arise from extended Tofts (ETM) DCEMRI analyses.
Goal(s): Develop and evaluate a model incorporating an avascular acellular compartment.
Approach: Synovitis and tenosynovitis DCEMRI from a rheumatoid arthritis (RA) clinical trial, measuring repeatability, and pharmacodynamic response to adalimumab.
Results: Despite the additional model parameter in the new model, repeatability, and ability to detect pharmacodynamic responses, were similar to standard ETM. Uptake rate constant repeatability CoV was 35% and pharmacodynamic treatment response ratio was 60% (p=0.027) (cf 39%, 54% and 0.027 for ETM). Extreme unphysiologic extravascular extracellular volumes ve were reported with ETM but not with the new model.
Impact: A robust DCEMRI analysis with better face validity increases confidence in the pathophysiologic interpretation of any pharmacodynamic changes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords